In the decade since the Human Genome Project heralded great things, the advent of biomarker validation and, in particular, personalized medicine have actually been slow to take hold. But there is another wrinkle limiting further development - a lack of clinically useful diagnostics, according to the Tufts Center for the Study of Drug Development. The issue is that many third-party payers are skeptical about whether certain tests are clinically useful. And Tufts says that pharmacogenomic experts foresee only moderate growth over the next five years in post hoc development of companion diagnostics to personalize already approved drugs, co-development of companion diagnostics and personalized drugs (read here).
